Sihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology

Reuters03-24

Sihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology

Sihuan said its majority-owned unit Xuanzhu Biopharma published final Phase 3 BRIGHT-2 results for CDK2/4/6 inhibitor piruoxib in combination with fulvestrant in JAMA Oncology.
The company stated the study reported a median progression-free survival of 14.7 months versus 7.3 months, with a 46% reduction in risk of disease progression or death.
Sihuan said the treatment achieved an objective response rate of 50.3% versus 16.7% in patients with measurable disease.
The company said the drug has received China approvals for use in HR+/HER2- advanced or metastatic breast cancer in combination with fulvestrant, as monotherapy, and in combination with an aromatase inhibitor.
Sihuan said two of the approved indications were added to China’s national reimbursement drug list, effective Jan. 1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260324-12065107), on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621306116?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621306116","market":"us","top_or_hot":-1,"title":"Sihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sihuan said its majority-owned unit Xuanzhu Biopharma published final Phase 3 BRIGHT-2 results for CDK2/4/6 inhibitor piruoxib in combination with fulvestrant in JAMA Oncology.\n        </li>\n<li>\n          The company stated the study reported a median progression-free survival of 14.7 months versus 7.3 months, with a 46% reduction in risk of disease progression or death.\n        </li>\n<li>\n          Sihuan said the treatment achieved an objective response rate of 50.3% versus 16.7% in patients with measurable disease.\n        </li>\n<li>\n          The company said the drug has received China approvals for use in HR+/HER2- advanced or metastatic breast cancer in combination with fulvestrant, as monotherapy, and in combination with an aromatase inhibitor.\n        </li>\n<li>\n          Sihuan said two of the approved indications were added to China’s national reimbursement drug list, effective Jan. 1.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHPHF\">Sihuan Pharmaceutical Holdings Group Ltd.</a> published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260324-12065107), on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-24 19:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sihuan said its majority-owned unit Xuanzhu Biopharma published final Phase 3 BRIGHT-2 results for CDK2/4/6 inhibitor piruoxib in combination with fulvestrant in JAMA Oncology.\n        </li>\n<li>\n          The company stated the study reported a median progression-free survival of 14.7 months versus 7.3 months, with a 46% reduction in risk of disease progression or death.\n        </li>\n<li>\n          Sihuan said the treatment achieved an objective response rate of 50.3% versus 16.7% in patients with measurable disease.\n        </li>\n<li>\n          The company said the drug has received China approvals for use in HR+/HER2- advanced or metastatic breast cancer in combination with fulvestrant, as monotherapy, and in combination with an aromatase inhibitor.\n        </li>\n<li>\n          Sihuan said two of the approved indications were added to China’s national reimbursement drug list, effective Jan. 1.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHPHF\">Sihuan Pharmaceutical Holdings Group Ltd.</a> published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260324-12065107), on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL3kmNYg:1","article_id":"2621306116","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621306116","pubTimestamp":1774352903,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sihuan said its majority-owned unit Xuanzhu Biopharma published final Phase 3 BRIGHT-2 results for CDK2/4/6 inhibitor piruoxib in combination with fulvestrant in JAMA Oncology.The company stated the study reported a median progression-free survival of 14.7 months versus 7.3 months, with a 46% reduction in risk of disease progression or death.Sihuan said the treatment achieved an objective response rate of 50.3% versus 16.7% in patients with measurable disease.The company said the drug has received China approvals for use in HR+/HER2- advanced or metastatic breast cancer in combination with fulvestrant, as monotherapy, and in combination with an aromatase inhibitor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Ho","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1593":"医美概念股","00460":"四环医药","BK1515":"抗疫概念","BK1191":"制药","BK1600":"工业大麻"},"translate_title":"四环医药子公司在JAMA Oncology上发表biloxcilib联合氟维司群的BRIGHT-2 3期结果","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":0.9},"content_text":"Sihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology\n    \n\n\n          Sihuan said its majority-owned unit Xuanzhu Biopharma published final Phase 3 BRIGHT-2 results for CDK2/4/6 inhibitor piruoxib in combination with fulvestrant in JAMA Oncology.\n        \n\n          The company stated the study reported a median progression-free survival of 14.7 months versus 7.3 months, with a 46% reduction in risk of disease progression or death.\n        \n\n          Sihuan said the treatment achieved an objective response rate of 50.3% versus 16.7% in patients with measurable disease.\n        \n\n          The company said the drug has received China approvals for use in HR+/HER2- advanced or metastatic breast cancer in combination with fulvestrant, as monotherapy, and in combination with an aromatase inhibitor.\n        \n\n          Sihuan said two of the approved indications were added to China’s national reimbursement drug list, effective Jan. 1.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260324-12065107), on March 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621306116","isCrawlerRequest":true}